Use of fidaxomicin for non-severe initial CDI, vancomycin for severe CDI, fidaxomicin for first recurrence, and FMT for subsequent recurrence (Strategy 44) cost an additional $478 for 0.009 QALYS gained per CDI patient, resulting in an ICER of $31,751 per QALY, below the willingness-to-pay threshold of $100,000/QALY.
However, limitations associated with FMT drive the need to identify key taxa for selective probiotic therapy for prevention, treatment and cure of human CDI.